Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis.

Abstract:
OBJECTIVES\nIrritable bowel syndrome (IBS) is a common gastrointestinal condition with a heterogeneous pathophysiology. An altered gut microbiome has been identified in some IBS patients, and fecal microbiota transplantation (FMT) has been suggested to treat IBS. We performed meta-analyses and systematic review of available randomized controlled trials (RCTs) to evaluate the efficacy of FMT in IBS.\n\n\nMETHODS\nWe performed a systematic literature search of MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Web of Science. Selection criteria included RCTs of FMT vs placebo using FMT excipients or autologous FMT in IBS. Meta-analyses were conducted to evaluate the summary relative risk (RR) and 95% confidence intervals (CIs) of combined studies for primary outcome of improvement in global IBS symptoms as measured by accepted integrative symptom questionnaires or dichotomous responses to questions of overall symptom improvement.\n\n\nRESULTS\nAmong 742 citations identified, 7 were deemed to be potentially relevant, of which 4 studies involving 254 participants met eligibility. No significant difference in global improvement of IBS symptoms was observed at 12 weeks in FMT vs placebo (RR = 0.93; 95% CI 0.48-1.79). Heterogeneity among studies was significant (I = 79%). Subgroup analyses revealed benefits of single-dose FMT using colonoscopy and nasojejunal tubes in comparison with autologous FMT for placebo treatment (number needed to treat = 5, RR = 1.59; 95% CI 1.06-2.39; I = 0%) and a reduction in likelihood of improvement of multiple-dose capsule FMT RCTs (number needed to harm = 3, RR = 0.54; 95% CI 0.34-0.85; I = 13%). Placebo response was 33.7% in nonoral FMT RCTs and 67.8% in capsule FMT RCTs. The Grading of Recommendations Assessment, Development and Evaluation quality of the body of evidence was very low.\n\n\nCONCLUSIONS\nCurrent evidence from RCTs does not suggest a benefit of FMT for global IBS symptoms. There remain questions regarding the efficacy of FMT in IBS as well as the lack of a clean explanation on the discrepant results among RCTs in subgroup analyses.
Author Listing： Dabo Xu;Vincent L Chen;Calen A Steiner;Jeffrey A Berinstein;Shanti Eswaran;Akbar K Waljee;Peter D R Higgins;Chung Owyang
Volume： None
Pages： None
DOI： 10.14309/ajg.0000000000000198
Language： English
Journal： The American journal of gastroenterology

AMERICAN JOURNAL OF GASTROENTEROLOGY

AM J GASTROENTEROL

影响因子：8.0 是否综述期刊：是 是否OA：否 是否预警：不在预警名单内 发行时间：1954 ISSN：0002-9270 发刊频率：Monthly 收录数据库：SCIE/Scopus收录 出版国家/地区：UNITED STATES 出版社：Springer Nature

期刊介绍

Aims and scopeAJG is published on behalf of the American College of Gastroenterology (ACG).As the leading clinical journal covering gastroenterology and hepatology, The American Journal of Gastroenterology (AJG) provides practical and professional support for clinicians dealing with the gastroenterological disorders seen most often in patients.Published with practicing clinicians in mind, the journal aims to be easily accessible, organizing its content by topic, both online and in print. Topics include:Colon and Small BowelEndoscopyEsophagusFunctional GI DisordersInflammatory Bowel DiseaseLiverPancreas and Biliary TractPathologyPediatricsNutrition/ObesityStomachAJG devotes itself to publishing timely medical research in gastroenterology and hepatology with:The notable Red Section which starts each issue by summarizing What's Hot in the Red Journal and publishing articles, debates and editorials covering techniques, methodologies, ethics, practice management and other important matters of concern to the international clinical community.Original Research at the highest level covering the spectrum of clinical gastroenterology and hepatology including the latest clinical studies on emerging developments.Study Highlights which summarize current knowledge and newly presented information in a particular article - a useful tool for the busy clinician.Editorials that highlight important issues in international gastroenterology and hepatology.In depth Clinical Reviews on hot topics in gastroenterology and liver disease.ACG Practice Guidelines present best practices for diagnosing and treating a range of disorders affecting the GI tract.CME credit opportunities, which are offered in every issue.Online supplementary materials accompanying many articles are available free online, including downloadable PowerPoint slides and videos.Supplements compliment every subscription on an annual basis.

Aims和scopeAJG代表美国胃肠病学会 (ACG) 出版。作为涵盖胃肠病学和肝脏病学的领先临床杂志，《美国胃肠病学杂志》 (AJG) 为临床医生提供实用和专业的支持，以处理患者中最常见到的胃肠病疾病。该期刊旨在易于访问，并按主题在线和印刷方式组织其内容。主题包括: 结肠和小碗食管食管功能性胃肠道疾病炎症性肠疾病胰腺和胆道疾病实践管理和国际临床界关注的其他重要事项。涵盖临床胃肠病学和肝病学领域的最高水平的原创研究，包括对新兴发展的最新临床研究。研究重点总结了当前的知识和新介绍的信息在特定的文章中-繁忙的临床医生的有用工具。强调国际胃肠病学和肝脏病学重要问题的社论。胃肠病学和肝病热点的深入临床评论。ACG实践指南提出了诊断和治疗一系列影响胃肠道疾病的最佳实践。CME信贷机会，每期都提供。许多文章附带的在线补充材料可免费在线获得，包括可下载的PowerPoint幻灯片和视频。每年补充一次订阅。

年发文量 243
国人发稿量 21
国人发文占比 8.64%
自引率 3.8%
平均录取率 约50%
平均审稿周期 平均12月
版面费 -
偏重研究方向 医学-胃肠肝病学
期刊官网 http://www.nature.com/ajg/index.html
投稿链接 https://www.editorialmanager.com/AJG

质量指标占比

研究类文章占比 OA被引用占比 撤稿占比 出版后修正文章占比
86.42% 12.23% 0.00% 2.17%

相关指数

{{ relationActiveLabel }}
{{ item.label }}

期刊预警不是论文评价，更不是否定预警期刊发表的每项成果。《国际期刊预警名单（试行）》旨在提醒科研人员审慎选择成果发表平台、提示出版机构强化期刊质量管理。

预警期刊的识别采用定性与定量相结合的方法。通过专家咨询确立分析维度及评价指标，而后基于指标客观数据产生具体名单。

具体而言，就是通过综合评判期刊载文量、作者国际化程度、拒稿率、论文处理费（APC）、期刊超越指数、自引率、撤稿信息等，找出那些具备风险特征、具有潜在质量问题的学术期刊。最后，依据各刊数据差异，将预警级别分为高、中、低三档，风险指数依次减弱。

《国际期刊预警名单（试行）》确定原则是客观、审慎、开放。期刊分区表团队期待与科研界、学术出版机构一起，夯实科学精神，打造气正风清的学术诚信环境！真诚欢迎各界就预警名单的分析维度、使用方案、值得关切的期刊等提出建议！

预警情况 查看说明

时间 预警情况
2024年02月发布的2024版 不在预警名单中
2023年01月发布的2023版 不在预警名单中
2021年12月发布的2021版 不在预警名单中
2020年12月发布的2020版 不在预警名单中

JCR分区 WOS分区等级：Q1区

版本 按学科 分区
WOS期刊SCI分区
WOS期刊SCI分区是指SCI官方（Web of Science）为每个学科内的期刊按照IF数值排 序，将期刊按照四等分的方法划分的Q1-Q4等级，Q1代表质量最高，即常说的1区期刊。
（2021-2022年最新版）
GASTROENTEROLOGY & HEPATOLOGY Q1

关于2019年中科院分区升级版（试行）

分区表升级版（试行）旨在解决期刊学科体系划分与学科发展以及融合趋势的不相容问题。由于学科交叉在当代科研活动的趋势愈发显著，学科体系构建容易引发争议。为了打破学科体系给期刊评价带来的桎梏，“升级版方案”首先构建了论文层级的主题体系，然后分别计算每篇论文在所属主题的影响力，最后汇总各期刊每篇论文分值，得到“期刊超越指数”，作为分区依据。

分区表升级版（试行）的优势：一是论文层级的主题体系既能体现学科交叉特点，又可以精准揭示期刊载文的多学科性；二是采用“期刊超越指数”替代影响因子指标，解决了影响因子数学性质缺陷对评价结果的干扰。整体而言，分区表升级版（试行）突破了期刊评价中学科体系构建、评价指标选择等瓶颈问题，能够更为全面地揭示学术期刊的影响力，为科研评价“去四唯”提供解决思路。相关研究成果经过国际同行的认可，已经发表在科学计量学领域国际重要期刊。

《2019年中国科学院文献情报中心期刊分区表升级版（试行）》首次将社会科学引文数据库（SSCI）期刊纳入到分区评估中。升级版分区表（试行）设置了包括自然科学和社会科学在内的18个大类学科。基础版和升级版（试行）将过渡共存三年时间，推测在此期间各大高校和科研院所仍可能会以基础版为考核参考标准。 提示：中科院分区官方微信公众号“fenqubiao”仅提供基础版数据查询，暂无升级版数据，请注意区分。

中科院分区 查看说明

版本 大类学科 小类学科 Top期刊 综述期刊
医学
1区
GASTROENTEROLOGY & HEPATOLOGY
胃肠肝病学
2区
 否 是
2021年12月
基础版
医学
1区
GASTROENTEROLOGY & HEPATOLOGY
胃肠肝病学
2区
 否 是
2021年12月
升级版
医学
1区
GASTROENTEROLOGY & HEPATOLOGY
胃肠肝病学
2区
 否 是
2020年12月
旧的升级版
医学
1区
GASTROENTEROLOGY & HEPATOLOGY
胃肠肝病学
1区
 否 是
2022年12月
最新升级版
医学
1区
GASTROENTEROLOGY & HEPATOLOGY
胃肠肝病学
2区
 否 是
翻译 润色 隐私声明 期刊介绍 SCI论文润色 SCI论文投稿
科研顾问
官方微信公众号